NEW YORK – Israeli cancer immunotherapeutics developer Biond Biologics said on Tuesday that it will receive $125 million upfront from Sanofi under an exclusive global licensing agreement to develop and commercialize its ILT2-targeting antagonist antibody BND-22 in solid tumors.
In addition to the upfront payment, Biond may also receive more than $1 billion in development, regulatory, and sales milestone payments from Sanofi, as well as tiered double-digit royalty payments.